Vasculitis trials

Trials closed

ALEVIATE

Anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis (AAV) is a severe disease of unknown cause when the immune system attacks and injures various tissues in the body. Patients with AAV develop kidney and lung disease and their lives…

MYCYC

There is a clear need for improved therapy in ANCA associated vasculitis where current treatments are toxic and contribute to poor outcomes. Conventional therapy combines cyclophosphamide with prednisolone but is associated with severe adverse…

PEXIVAS

Granulomatosis with polyangiitis (Wegener's) (WG) and microscopic polyangiitis (MPA) are syndromes of primary systemic vasculitis associated with anti-neutrophil cytoplasm antibodies (ANCA). Together, these syndromes are grouped as ANCA-…

RITAZAREM

Rituximab is now established as an effective drug for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis following major European and US trials reported in 2010. After a time, its effect wears off and the disease can return. This occurs in at…